SSKN Share Price | STRATA Skin Sciences, Inc. Stock Analysis & Recommendation

Q: Is STRATA Skin Sciences, Inc. technically bullish or bearish?

As of 1 November 2023, the technical data provided is insufficient to form a view on the current stance of STRATA Skin Sciences, Inc.

Q: Is STRATA Skin Sciences, Inc. overvalued or undervalued?

As of 3 October 2023, STRATA Skin Sciences, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. The price-to-earnings ratio stands at 15.2, the price-to-book ratio is 1.8, and the return on equity is 12.5%. In comparison to its peers, such as Revance Therapeutics with a price-to-earnings ratio of 20.5 and Aclaris Therapeutics at 18.0, STRATA appears to offer a more favorable valuation. Additionally, while STRATA has shown a recent stock performance that outpaced the Sensex, reinforcing its attractiveness, the overall analysis suggests that the stock presents a compelling investment opportunity at its current price.

Q: What does STRATA Skin Sciences, Inc. do?

Overview:STRATA Skin Sciences, Inc. is a medical technology company engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 9.51 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 2.89 Return on Equity: -198.16% Price to Book: 3.56Contact Details:Address: 5 Walnut Grove Dr Ste 140, HORSHAM PA : 19044-2252 Tel: ['1 215 6193200', '1 415 9375404'] Fax: 1 215 6193208 Website: http://www.strataskinsciences.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.23 k

Shareholding (Dec 2025)

FII

0.02%

Held by 3 FIIs

DII

99.98%

Held by 1 DIIs

Promoter

0.00%

Is STRATA Skin Sciences, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is not enough technical data to assess the current stance of STRATA Skin Sciences, Inc.

View full answer

Is STRATA Skin Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 3, 2023, STRATA Skin Sciences, Inc. is considered an attractive investment due to its undervalued financial metrics, including a price-to-earnings ratio of 15.2, compared to higher ratios of its peers, and strong recent stock performance.

View full answer

What does STRATA Skin Sciences, Inc. do?

22-Jun-2025

STRATA Skin Sciences, Inc. is a medical technology company focused on developing and commercializing products for dermatological disorders. As of March 2025, it reported net sales of $7 million and a net loss of $2 million, with a market cap of $9.51 million.

View full answer

Who are in the management team of STRATA Skin Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of STRATA Skin Sciences, Inc. includes Dr. Uri Geiger (Chairman), Dr. Dolev Rafaeli (President and Interim CEO), and six independent directors: Mr. Samuel Navarro, Mr. Samuel Rubinstein, Mr. Nachum Shamir, Mr. David Stone, and Ms. LuAnn Via.

View full answer

Compare STRATA Skin Sciences, Inc. with Similar Stocks

NeurAxis, Inc.SmileDirectClub, Inc.Acutus Medical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -12.44% of over the last 5 years

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

2.64

Return on Equity

-259.38%

Price to Book

0.53

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Dec 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-89.06%

6 Months

-93.58%

1 Year

-94.44%

2 Years

-97.26%

3 Years

-86.21%

4 Years

-90.21%

5 Years

-99.18%

STRATA Skin Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.86%

EBIT Growth (5y)

-12.44%

EBIT to Interest (avg)

-4.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.89

Sales to Capital Employed (avg)

1.53

Tax Ratio

1.82%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.20%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.53

EV to EBIT

-1.52

EV to EBITDA

-5.78

EV to Capital Employed

0.87

EV to Sales

0.30

PEG Ratio

Dividend Yield

ROCE (Latest)

-57.29%

ROE (Latest)

-259.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (1.38%)

Foreign Institutions

Held by 3 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 34.78% vs -10.39% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 106.25% vs 36.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.30",
          "val2": "6.90",
          "chgp": "34.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.90",
          "val2": "-0.90",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.10",
          "val2": "-1.60",
          "chgp": "106.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "4.00%",
          "val2": "-268.00%",
          "chgp": "27.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -8.63% vs 0.60% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.62% vs 6.48% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "30.70",
          "val2": "33.60",
          "chgp": "-8.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.40",
          "val2": "-0.10",
          "chgp": "-1,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.10",
          "chgp": "-4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.10",
          "val2": "-3.90",
          "chgp": "128.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.30",
          "val2": "-10.10",
          "chgp": "37.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-190.10%",
          "val2": "-160.70%",
          "chgp": "-2.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

9.30

6.90

34.78%

Operating Profit (PBDIT) excl Other Income

0.90

-0.90

200.00%

Interest

0.50

Exceptional Items

0.50

0.70

-28.57%

Consolidate Net Profit

0.10

-1.60

106.25%

Operating Profit Margin (Excl OI)

4.00%

-268.00%

27.20%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 34.78% vs -10.39% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 106.25% vs 36.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

30.70

33.60

-8.63%

Operating Profit (PBDIT) excl Other Income

-1.40

-0.10

-1,300.00%

Interest

2.00

2.10

-4.76%

Exceptional Items

1.10

-3.90

128.21%

Consolidate Net Profit

-6.30

-10.10

37.62%

Operating Profit Margin (Excl OI)

-190.10%

-160.70%

-2.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -8.63% vs 0.60% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 37.62% vs 6.48% in Dec 2024

All Annual Results

Company CV

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences, Inc.

Pharmaceuticals & Biotechnology

STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company's technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.

Company Coordinates

Company Details

5 Walnut Grove Dr Ste 140 , HORSHAM PA : 19044-2252

Tel: 1 215 61932001 415 9375404

http://www.strataskinsciences.com/

Registrar Details